Amanote Research
Register
Sign In
Optimized Dendritic Cell (DC) Vaccine Regimen
Science-Business eXchange
doi 10.1038/scibx.2011.469
Full Text
Open PDF
Abstract
Available in
full text
Date
April 1, 2011
Authors
Unknown
Publisher
Springer Science and Business Media LLC
Related search
Dendritic Cell–specific ICAM-3 Grabbing Nonintegrin (DC-SIGN; CD209)
Science-Business eXchange
Gemcitabine and Docetaxel as a Novel Treatment Regimen for Blastic Plasmacytoid Dendritic Cell Neoplasm
American Journal of Hematology
Hematology
Lentiviral Vector-Based Dendritic Cell Vaccine Suppresses HIV Replication in Humanized Mice
Molecular Therapy
Molecular Medicine
Molecular Biology
Pharmacology
Medicine
Genetics
Drug Discovery
Optimized Dose Regimen for Whole-Body FDG-PET Imaging
EJNMMI Research
Nuclear Medicine
Radiology
Imaging
Optimized Multiport DC/DC Converter for Vehicle Drivetrains: Topology and Design Optimization
Applied Sciences (Switzerland)
Instrumentation
Materials Science
Fluid Flow
Engineering
Computer Science Applications
Process Chemistry
Transfer Processes
Technology
Results of a Phase I/Ii Clinical Trial of BPX-101, a Novel Drug-Activated Dendritic Cell (DC) Vaccine for Metastatic Castration-Resistant Prostate Cancer (mCRPC).
Journal of Clinical Oncology
Cancer Research
Medicine
Oncology
Optimized Mucosal MVA Prime/Soluble Gp120 Boost Vaccination Regimen Induces Similar Antibody Responses as an Intramuscular Regimen
Journal of Virology
Insect Science
Immunology
Microbiology
Virology
The Influence of HIV-1 Subtype in the Response to Therapeutic Dendritic Cell Vaccine
Open AIDS Journal
Environmental
Public Health
Infectious Diseases
Virology
Occupational Health
Extensive Repertoire of Membrane-Bound and Soluble Dendritic Cell-Specific ICAM-3-grabbing Nonintegrin 1 (DC-SIGN1) and DC-SIGN2 Isoforms
Journal of Biological Chemistry
Biochemistry
Cell Biology
Molecular Biology
